Stockscreener 앱 받기
53.01
6.55%
3.26
시간 외 거래:
52.02
-0.99
-1.87%
전일 마감가:
$49.75
열려 있는:
$50.71
하루 거래량:
3.72M
Relative Volume:
2.11
시가총액:
$6.34B
수익:
$18.47M
순이익/손실:
$-589.53M
주가수익비율:
-10.08
EPS:
-5.26
순현금흐름:
$-399.80M
1주 성능:
+50.04%
1개월 성능:
+46.60%
6개월 성능:
+20.81%
1년 성능:
-5.22%
1일 변동 폭
$49.86
$54.00
1주일 범위
$44.91
$54.00
52주 변동 폭
$29.31
$59.39
Cytokinetics Inc Stock (CYTK) Company Profile
명칭
Cytokinetics Inc
전화
(650) 624-3000
주소
350 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
CYTK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYTK
Cytokinetics Inc
|
53.01 | 5.95B | 18.47M | -589.53M | -399.80M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytokinetics Inc Stock (CYTK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | Raymond James | Mkt Perform |
| 2025-04-24 | 개시 | Barclays | Overweight |
| 2025-02-07 | 개시 | Citigroup | Buy |
| 2025-01-22 | 개시 | Stifel | Buy |
| 2024-11-08 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-13 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-01-24 | 다운그레이드 | UBS | Buy → Neutral |
| 2024-01-05 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-09 | 개시 | Goldman | Buy |
| 2023-11-07 | 개시 | B. Riley Securities | Buy |
| 2023-08-15 | 개시 | SVB Securities | Outperform |
| 2023-02-17 | 개시 | BofA Securities | Neutral |
| 2022-12-23 | 재확인 | Needham | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-10-11 | 개시 | UBS | Buy |
| 2022-01-28 | 개시 | Goldman | Buy |
| 2021-12-22 | 개시 | Oppenheimer | Outperform |
| 2021-12-10 | 개시 | JP Morgan | Overweight |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-03-12 | 개시 | Wolfe Research | Outperform |
| 2021-02-18 | 개시 | Barclays | Overweight |
| 2021-01-20 | 재확인 | H.C. Wainwright | Buy |
| 2020-10-29 | 개시 | Goldman | Neutral |
| 2020-07-10 | 개시 | Raymond James | Strong Buy |
| 2020-05-05 | 개시 | Mizuho | Buy |
| 2020-04-09 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-10 | 재개 | Morgan Stanley | Equal-Weight |
| 2017-11-22 | 재확인 | Morgan Stanley | Overweight |
| 2017-11-22 | 다운그레이드 | Needham | Strong Buy → Buy |
| 2017-11-21 | 재확인 | H.C. Wainwright | Buy |
| 2017-07-31 | 개시 | Morgan Stanley | Overweight |
| 2017-03-08 | 개시 | Rodman & Renshaw | Buy |
| 2017-02-06 | 업그레이드 | Needham | Buy → Strong Buy |
| 2016-12-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-07-28 | 재확인 | Needham | Buy |
| 2015-11-10 | 재확인 | FBR Capital | Outperform |
| 2015-11-09 | 재확인 | ROTH Capital | Buy |
| 2015-07-24 | 재확인 | MLV & Co | Buy |
| 2014-12-31 | 재확인 | ROTH Capital | Buy |
| 2014-11-04 | 업그레이드 | MLV & Co | Hold → Buy |
| 2014-04-28 | 재확인 | Needham | Buy |
모두보기
Cytokinetics Inc 주식(CYTK)의 최신 뉴스
Will earnings trigger a reversal in Cytokinetics Incorporated2025 Key Highlights & Smart Swing Trading Alerts - Newser
Cytokinetics (CYTK) Rockets 40.45% as Aficamten Results Promising - MSN
Multi asset correlation models including Cytokinetics Incorporated2025 Price Action Summary & Detailed Earnings Play Alerts - Newser
Is Cytokinetics Incorporated’s ROE strong enough2025 Market Outlook & Daily Growth Stock Tips - خودرو بانک
What’s the analyst consensus on Cytokinetics Incorporated2025 Key Highlights & AI Driven Price Predictions - خودرو بانک
Is Cytokinetics Incorporated stock a good pick for beginners2025 Sector Review & Smart Money Movement Tracker - خودرو بانک
Published on: 2025-09-05 22:58:57 - خودرو بانک
Is Cytokinetics Incorporated a top pick in the sectorDip Buying & Weekly Return Optimization Alerts - خودرو بانک
Braveheart licenses Hengrui's heart drug HRS-1893 in $1B deal - BioWorld MedTech
Is Cytokinetics Incorporated stock bottoming outTrade Signal Summary & Safe Capital Allocation Plans - Newser
Cytokinetics patents new MYBPC2 inhibitors - BioWorld MedTech
Cytokinetics shares rise 1.19% premarket after Cantor Global Healthcare Conference fireside chat. - AInvest
Predicting Cytokinetics Incorporated trend using moving averagesJuly 2025 Patterns & Safe Entry Momentum Tips - Newser
Real time social sentiment graph for Cytokinetics IncorporatedMarket Movement Recap & AI Powered Market Entry Strategies - Newser
Updated: Hengrui does another US deal, this time in Cytokinetics' cardio arena - Endpoints News
Using Python tools to backtest Cytokinetics Incorporated strategiesJuly 2025 Sector Moves & Weekly Market Pulse Updates - Newser
Spinal Muscular Atrophy Market Positioned for Accelerated - openPR.com
Will Cytokinetics Incorporated benefit from macro trendsQuarterly Trade Report & Technical Pattern Recognition Alerts - Newser
Cytokinetics Incorporated stock prediction for this weekJuly 2025 PreEarnings & Consistent Profit Trading Strategies - Newser
How to read the order book for Cytokinetics Incorporated2025 Short Interest & Community Consensus Picks - Newser
How to manage a losing position in Cytokinetics IncorporatedJuly 2025 News Drivers & Proven Capital Preservation Tips - Newser
Movement Recap: Is Cytokinetics Incorporated a top pick in the sector2025 Trading Volume Trends & AI Based Trade Execution Alerts - خودرو بانک
Cytokinetics Gains on Positive Late-Stage Cardiomyopathy Study Results - Yahoo Finance
Cytokinetics: Evercore ISI Group raises PT to $80 from $60, maintains Outperform. - AInvest
Cytokinetics shares fall 1.15% premarket after insider sold shares worth $337,800. - AInvest
Will Cytokinetics Incorporated benefit from rate cutsInsider Selling & Risk Controlled Stock Alerts - خودرو بانک
Understanding Cytokinetics Incorporated’s price movement2025 Biggest Moves & Community Trade Idea Sharing Platform - Newser
Does Cytokinetics Incorporated show high probability of reboundJuly 2025 PostEarnings & Long Hold Capital Preservation Tips - Newser
Can Cytokinetics Incorporated recover in the next quarterMarket Rally & Free Safe Capital Growth Stock Tips - Newser
Applying chart zones and confluence areas to Cytokinetics Incorporated2025 Year in Review & Growth Oriented Trade Recommendations - Newser
What’s next for Cytokinetics Incorporated stock pricePortfolio Profit Report & Long-Term Growth Plans - Newser
Technical signs of recovery in Cytokinetics IncorporatedMarket Sentiment Summary & Safe Entry Zone Tips - Newser
Detecting support and resistance levels for Cytokinetics IncorporatedChart Signals & High Win Rate Trade Alerts - Newser
How high can Cytokinetics Incorporated stock goJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - Newser
Cytokinetics’ Aficamten with breakthrough Phase III results - European Biotechnology Magazine
Cytokinetics Shares Jump 40.45% on Aficamten HCM Data $630M Volume Ranks 162nd - AInvest
Is Cytokinetics Incorporated on track to beat earnings2025 Key Highlights & Smart Swing Trading Techniques - خودرو بانک
Stifel raises Cytokinetics stock price target to $96 on bullish outlook - Investing.com Canada
Should I buy Cytokinetics Incorporated stock nowIPO Watch & Daily Profit Maximizing Trade Tips - khodrobank.com
Cytokinetics’ Aficamten Shows Head-To-Head Advantage Vs. Beta Blockers - insights.citeline.com
Growth or Bubble? Decoding Cytokinetics’ Surge - timothysykes.com
These Stocks Moved the Most Today: Nvidia, PepsiCo, Tesla, Kraft Heinz, Constellation Brands, Cytokinetics, and More - Barron's
Cytokinetics at Citi’s Biopharma Conference: Aficamten’s Promising Path - Investing.com
Cytokinetics Skyrockets On 'Provocative' Results In Heart Disease - Investor's Business Daily
Aficamten Bests Metoprolol in Cytokinetics' Trial for Obstructive Hypertrophic Cardiomyopathy - PharmTech
Bitcoin gains, Frontier upgraded, Cytokinetics trial results - Yahoo Finance
Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential (NASDAQ:CYTK) - Seeking Alpha
Cytokinetics says heart disease drug more effective than standard-of-care, shares jump - TradingView
Cytokinetics’ Aficamten: Navigating Regulatory Hurdles and Market Potential in the OHCM Space - AInvest
Cytokinetics Appoints New Director Amid Revenue Boost and Strategic Moves - StocksToTrade
Board Appointment Boosts Cytokinetics’ Growth Projections - timothysykes.com
Cytokinetics Inc (CYTK) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
자본화:
|
볼륨(24시간):